JOURNEY MEDICAL CORP (DERM) Stock Overview
USA - NASDAQ:DERM - US48115J1097 - Common Stock
DERM Key Statistics, Chart & Performance
The current stock price of DERM is 8.13 USD. In the past month the price increased by 12.96%. In the past year, price increased by 29.98%.
DERM Latest News, Press Relases and Analysis
DERM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.78 | 776.19B | ||
| JNJ | JOHNSON & JOHNSON | 18.01 | 450.19B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.61 | 256.13B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.95 | 238.94B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.38 | 231.28B | ||
| MRK | MERCK & CO. INC. | 11.3 | 217.38B | ||
| PFE | PFIZER INC | 7.23 | 139.30B | ||
| SNY | SANOFI-ADR | 11.55 | 124.44B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.36 | 87.16B | ||
| GSK | GSK PLC-SPON ADR | 9.75 | 87.89B | ||
| ZTS | ZOETIS INC | 23.38 | 64.44B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.36 | 44.53B |
Related stock screener links
About DERM
Company Profile
Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company is headquartered in Scottsdale, Arizona and currently employs 41 full-time employees. The company went IPO on 2021-11-12. The firm is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
Company Info
JOURNEY MEDICAL CORP
9237 E Via De Ventura Blvd., Suite 105, Suite 105
Scottsdale ARIZONA 94025 US
CEO: Thomas G. Wiggans
Employees: 41
Phone: 14804346670
JOURNEY MEDICAL CORP / DERM FAQ
What does JOURNEY MEDICAL CORP do?
Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company is headquartered in Scottsdale, Arizona and currently employs 41 full-time employees. The company went IPO on 2021-11-12. The firm is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
What is the current price of DERM stock?
The current stock price of DERM is 8.13 USD. The price increased by 1.37% in the last trading session.
Does DERM stock pay dividends?
DERM does not pay a dividend.
What is the ChartMill technical and fundamental rating of DERM stock?
DERM has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for DERM stock?
11 analysts have analysed DERM and the average price target is 12.04 USD. This implies a price increase of 48.04% is expected in the next year compared to the current price of 8.13.
Is JOURNEY MEDICAL CORP (DERM) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DERM.
Is JOURNEY MEDICAL CORP (DERM) expected to grow?
The Revenue of JOURNEY MEDICAL CORP (DERM) is expected to grow by 22.4% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
DERM Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to DERM. When comparing the yearly performance of all stocks, DERM is one of the better performing stocks in the market, outperforming 80.07% of all stocks.
DERM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DERM. DERM has a bad profitability rating. Also its financial health evaluation is rather negative.
DERM Financial Highlights
Over the last trailing twelve months DERM reported a non-GAAP Earnings per Share(EPS) of -0.66. The EPS decreased by -3200% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.77% | ||
| ROE | -45.4% | ||
| Debt/Equity | 1.11 |
DERM Forecast & Estimates
11 analysts have analysed DERM and the average price target is 12.04 USD. This implies a price increase of 48.04% is expected in the next year compared to the current price of 8.13.
For the next year, analysts expect an EPS growth of 68.5% and a revenue growth 22.4% for DERM